[{"address1": "697 Burke Road", "address2": "Suite 201", "city": "Camberwell", "state": "VIC", "zip": "3124", "country": "Australia", "phone": "61 3 9092 0475", "fax": "61 3 8678 1269", "website": "https://www.tryptherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jason  Carroll", "title": "MD, CEO & Executive Director", "fiscalYear": 2024, "totalPay": 903036, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James P. Gilligan MSIB, Ph.D.", "age": 72, "title": "President & Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 314740, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Leo Ntoumenopoulos", "age": 41, "title": "Executive Director", "yearBorn": 1983, "fiscalYear": 2024, "totalPay": 27595, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William James Garner M.D.", "age": 58, "title": "Founder & MD", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 41239, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hamish  George B.Com., C.A.", "title": "CFO & Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.", "age": 75, "title": "Chief Medical Officer", "yearBorn": 1949, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.015, "open": 0.0252, "dayLow": 0.0252, "dayHigh": 0.0252, "regularMarketPreviousClose": 0.015, "regularMarketOpen": 0.0252, "regularMarketDayLow": 0.0252, "regularMarketDayHigh": 0.0252, "payoutRatio": 0.0, "volume": 40000, "regularMarketVolume": 40000, "averageVolume": 44095, "averageVolume10days": 81559, "averageDailyVolume10Day": 81559, "bid": 0.011, "ask": 0.028, "bidSize": 0, "askSize": 184960, "marketCap": 30851698, "fiftyTwoWeekLow": 0.0007, "fiftyTwoWeekHigh": 0.0385, "priceToSalesTrailing12Months": 23.244986, "fiftyDayAverage": 0.015954, "twoHundredDayAverage": 0.0163925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 11219859, "profitMargins": 0.0, "floatShares": 778566306, "sharesOutstanding": 1438919936, "heldPercentInsiders": 0.41694, "heldPercentInstitutions": 0.0072000003, "impliedSharesOutstanding": 2804699904, "bookValue": 0.003, "priceToBook": 3.6666665, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -7371084, "trailingEps": -0.02, "lastSplitFactor": "1:2.5", "lastSplitDate": 1713139200, "enterpriseToRevenue": 8.454, "enterpriseToEbitda": -2.426, "52WeekChange": 0.100000024, "SandP52WeekChange": 0.13161862, "quoteType": "EQUITY", "currentPrice": 0.011, "recommendationKey": "none", "totalCash": 2870577, "totalCashPerShare": 0.002, "ebitda": -4624144, "totalDebt": 49795, "quickRatio": 3.694, "currentRatio": 3.865, "totalRevenue": 1327241, "debtToEquity": 1.176, "revenuePerShare": 0.003, "grossProfits": -1020004, "operatingCashflow": -7200070, "grossMargins": -0.76851, "ebitdaMargins": 0.0, "operatingMargins": -3.4901502, "financialCurrency": "AUD", "symbol": "TYPTF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "firstTradeDateMilliseconds": 1720186200000, "regularMarketChange": -0.0039999997, "regularMarketDayRange": "0.0252 - 0.0252", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 44095, "fiftyTwoWeekLowChange": 0.0103, "fiftyTwoWeekLowChangePercent": 14.714287, "fiftyTwoWeekRange": "7.0E-4 - 0.0385", "fiftyTwoWeekHighChange": -0.0275, "fiftyTwoWeekHighChangePercent": -0.71428573, "fiftyTwoWeekChangePercent": 10.000002, "earningsTimestampStart": 1756465140, "earningsTimestampEnd": 1756987200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.02, "fiftyDayAverageChange": -0.004954001, "fiftyDayAverageChangePercent": -0.3105178, "twoHundredDayAverageChange": -0.0053924993, "twoHundredDayAverageChangePercent": -0.32896137, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Tryp Therapeutics Inc.", "nameChangeDate": "2025-07-16", "marketState": "CLOSED", "hasPrePostMarketData": false, "shortName": "TRYPTAMINE THERAPEUTICS LTD.", "cryptoTradeable": false, "corporateActions": [], "regularMarketTime": 1752796800, "exchange": "PNK", "messageBoardId": "finmb_693911067", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -26.666666, "regularMarketPrice": 0.011, "displayName": "Tryptamine Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-19"}]